Essential Certificate of Analysis Parameters for R-(-)-3-(Carbamoylmethyl)-5-Methylhexanoic Acid
- Critical Quality Attributes: COA must verify chiral purity ≥98% and specific impurity limits aligned with ICH guidelines.
- Physical Constants: Verified melting point and molecular weight data ensure identity matching CAS 181289-33-8.
- Supply Chain Security: Bulk procurement requires GMP-aligned documentation from a trusted global manufacturer.
In the pharmaceutical manufacturing sector, the reliability of key intermediates dictates the success of the final Active Pharmaceutical Ingredient (API) production. For the synthesis of Pregabalin, the stereochemical integrity of the precursor is non-negotiable. The (R)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid serves as a pivotal chiral building block. Consequently, the Certificate of Analysis (COA) is not merely a administrative document but a technical blueprint verifying identity, purity, and safety. Procurement teams and quality assurance units must scrutinize these specifications to ensure batch-to-batch consistency and regulatory compliance.
Defining Critical Quality Attributes in the COA
A robust COA for this intermediate must transcend basic identity testing. It requires detailed analytical data confirming the industrial purity and enantiomeric excess. The molecular formula C9H17NO3 and molecular weight of 187.24 g/mol are the foundational identifiers. However, in a commercial manufacturing process, the presence of the S-enantiomer or related organic impurities can detrimentally affect downstream reaction yields. Therefore, the COA should explicitly state the method of analysis, typically High-Performance Liquid Chromatography (HPLC) using chiral columns, alongside the acceptance criteria.
When evaluating suppliers for R-(-)-3-(Carbamoylmethyl)-5-methylhexanoic acid, buyers should prioritize vendors who provide comprehensive impurity profiles. This includes limits for residual solvents, heavy metals, and specific process-related impurities. The appearance should be consistent, typically described as a white to off-white crystalline powder, indicating proper crystallization and drying protocols during production.
Technical Specifications and Physical Constants
To facilitate quality control comparisons, the following table outlines the standard technical specifications expected for high-grade batches of this intermediate. These values are derived from standard pharmacopeial expectations and industry norms for CAS 181289-33-8.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 181289-33-8 | Verification |
| Molecular Formula | C9H17NO3 | Calculation |
| Molecular Weight | 187.24 g/mol | Calculation |
| Appearance | White to Off-White Powder | Visual Inspection |
| Purity (HPLC) | ≥ 98.0% | Area Normalization |
| Enantiomeric Excess | ≥ 98.0% (R-isomer) | Chiral HPLC |
| Melting Point | 130°C – 135°C | DSC / Capillary |
| Loss on Drying | ≤ 0.5% | Karl Fischer / LOD |
| Residual Solvents | Compliant with ICH Q3C | GC-Headspace |
Interpreting Chiral Purity and Impurity Profiles
The designation (3R)-3-(2-amino-2-oxoethyl)-5-methylhexanoic acid highlights the specific stereochemistry required. In the context of Pregabalin synthesis, the presence of the S-isomer is a critical quality attribute. A high-quality synthesis route will minimize the formation of the undesired enantiomer. The COA must report the enantiomeric ratio clearly. If the chiral purity drops below 98%, it may necessitate additional recrystallization steps, increasing the overall cost of goods and reducing the final API yield.
Furthermore, the impurity profile should account for 3-(carbamoylmethyl)-5-methylhexanoic acid related substances. These often include unreacted starting materials, hydrolysis products, or dimerization byproducts. Advanced manufacturers utilize validated LC-MS methods to identify and quantify these trace components. Understanding these profiles allows process chemists to adjust reaction parameters such as temperature, pH, and catalyst loading to optimize the manufacturing process for future batches.
Regulatory Alignment and GMP Compliance
For intermediates intended for use in GMP-regulated API production, the COA must align with ICH Q3 guidelines regarding impurities. This includes qualifying any impurity present above 0.10%. Documentation should also include stability data to support the claimed shelf life, typically validated for 24 to 60 months under recommended storage conditions. Storage temperature is generally maintained at ambient or controlled room temperature, though some specifications suggest +5°C for long-term preservation of chiral integrity.
Transparency in the supply chain is paramount. A reliable global manufacturer will provide not only the COA but also access to Method Validation Reports and Stability Study Summaries upon request. This level of documentation reduces audit friction and ensures continuity of supply. Companies like NINGBO INNO PHARMCHEM CO.,LTD. specialize in delivering these high-specification intermediates with full traceability, ensuring that every batch meets the rigorous demands of international pharmaceutical clients.
Commercial Considerations for Bulk Procurement
Beyond technical specifications, commercial viability depends on consistent bulk price structures and reliable lead times. The R-isomer of 3-(carbamoylmethyl)-5-methylhexanoic acid is a high-value intermediate, and pricing often correlates with the guaranteed chiral purity. Procurement officers should negotiate based on volume tiers while ensuring that cost reductions do not compromise the analytical standards outlined in the COA.
In conclusion, the COA for this chemical entity is a critical tool for risk management in pharmaceutical synthesis. By enforcing strict adherence to purity, chirality, and regulatory documentation, manufacturers can safeguard their production lines. Partnering with an experienced supplier ensures that the COA reflects not just compliance, but a commitment to excellence in chemical manufacturing.